The determination is predicated on information from latest medical trials that means that the chance of amputation, whereas nonetheless elevated with the drug, is decrease than beforehand attributed, when monitored appropriately, the well being regulator stated.
Invokana was authorized in 2017 for use with diet and train to decrease blood sugar in adults with kind 2 diabetes.
Reviews of latest medical information additionally confirmed the drug had further coronary heart and kidney associated advantages, the company stated.
Invokana generated gross sales of $790 million in 2019, a decline of 20% from a 12 months earlier.
(Reporting by Trisha Roy in Bengaluru; Editing by Sriraj Kalluvila)